BJDX
Bluejay Diagnostics, Inc.0.9664
-0.0436-4.32%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
1.75MP/E (TTM)
0.01Basic EPS (TTM)
164.37Dividend Yield
0%Recent Filings
8-K
Insiders buy $125K shares
Bluejay Diagnostics executed a private placement on March 14, 2026, selling 62,500 common shares at $2.00 each to insiders—CEO Neil Dey, Chair Donald Chase, and directors—for $125,000 gross proceeds, closing March 17. Insiders chipped in equally. Securities remain unregistered, diluting outsiders slightly while signaling leadership commitment.
8-K
Responds to acquisition pitch
Bluejay Diagnostics responded to NorthStrive Fund II's March 11 letter proposing a Phase-1-ready therapeutic acquisition for refractory chronic cough. The company prioritizes its Symphony platform, SYMON II study completion, manufacturing scale-up, and FDA submission to preserve cash. Board will evaluate the limited-info opportunity for synergy. No decision yet.
8-K
IL-6 abstract accepted at SAEM
Bluejay Diagnostics announced on March 12, 2026, that an abstract on its Symphony IL-6 Test from the SYMON-I pilot study was accepted for presentation at the 2026 SAEM Annual Meeting in Atlanta, May 18–21. The data links emergency department IL-6 levels to organ dysfunction via SOFA scores in sepsis patients headed to ICU. Presentation spotlights biomarker potential. SYMON-II validation study advances toward FDA 510(k).
10-K
FY2025 results
Bluejay Diagnostics narrowed its FY2025 operating loss to $7.0M from $7.2M in 2024, with R&D expenses dropping 12% to $3.0M amid reduced technology transfer efforts, while G&A rose 6% to $3.9M on higher franchise taxes. Q4 saw SYMON-II enrollment hit 583 of 750 patients, accelerating pivotal trial momentum despite cartridge manufacturing delays with Sanyoseiko. Cash stood at $5.2M by year-end, funding ops to Q3 2026; April and October financings added $7.1M but signal dilution risks. No revenue yet. Toray license termination looms if manufacturing lags.
8-K
Bluejay's 2025 financials, 2026 plans
Bluejay Diagnostics reported $5.2 million in cash and $6.0 million in stockholders' equity as of December 31, 2025, after $6.8 million net losses, bolstered by $3.8 million warrant inducement and $4.5 million PIPE financings. SYMON II clinical study advances on track toward regulatory submission; manufacturing scales up. Needs $20 million more capital by 2027 end. Cash fuels runway.
BDX
Becton, Dickinson and Company
196.39-3.70
BIAF
bioAffinity Technologies, Inc.
1.38-0.10
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
BMRA
Biomerica, Inc.
2.37-0.08
BRKR
Bruker Corporation
44.96-0.71
CODX
Co-Diagnostics, Inc.
0.25-0.02
DGX
Quest Diagnostics Incorporated
178.66-5.45
IDXG
Interpace Biosciences, Inc.
1.14-0.02
LUCD
Lucid Diagnostics Inc.
1.12+0.01
QTRX
Quanterix Corporation
7.36-0.05